Literature DB >> 7536825

Neuronal regeneration enhances the expression of the immunophilin FKBP-12.

W E Lyons1, J P Steiner, S H Snyder, T M Dawson.   

Abstract

Immunophilins are a group of proteins that serve as receptors for the immunosuppressant drugs cyclosporin A and FK506. The immunophilin designated FK-506 binding protein-12 (FKBP-12) is concentrated more than 10 times higher in the brain than in immune tissues. The complex of FK506 and FKBP-12 inhibits the calcium activated phosphatase, calcineurin, increasing phosphorylated levels of calcineurin substrates with growth associated protein-43 (GAP-43), being most prominent in the brain. We now demonstrate an association of FKBP-12 with neuronal regeneration and GAP-43 disposition. Facial nerve crush markedly augments expression of FKBP-12 mRNA in the facial nucleus with a time course paralleling changes in GAP-43 mRNA. Following sciatic nerve lesions, similar increases in FKBP-12 mRNA occur in lumbar motor neurons and dorsal root ganglia neuronal cells. Increased FKBP-12 expression appears linked to regeneration rather than degeneration as facial nerve lesions elicited by ricin injection, which produce neuronal death without regeneration, fail to augment FKBP-12 expression in the facial nucleus. The time course for accumulation of FKBP-12 in sciatic nerve segments following nerve crush indicates rapid axonal transport at a rate similar to GAP-43.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7536825      PMCID: PMC6577794     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  18 in total

1.  Age-related changes of sodium-dependent D-[3H]aspartate and [3H]FK506 binding in rat brain.

Authors:  T Araki; H Kato; K Shuto; T Fujiwara; Y Itoyama
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

2.  The effects of cold preservation and subimmunosuppressive doses of FK506 on axonal regeneration in murine peripheral nerve isografts.

Authors:  Terence M Myckatyn; Daniel A Hunter; Susan E Mackinnon
Journal:  Can J Plast Surg       Date:  2003

Review 3.  Peptidyl-Proline Isomerases (PPIases): Targets for Natural Products and Natural Product-Inspired Compounds.

Authors:  Bryan M Dunyak; Jason E Gestwicki
Journal:  J Med Chem       Date:  2016-07-25       Impact factor: 7.446

4.  Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models.

Authors:  J P Steiner; G S Hamilton; D T Ross; H L Valentine; H Guo; M A Connolly; S Liang; C Ramsey; J H Li; W Huang; P Howorth; R Soni; M Fuller; H Sauer; A C Nowotnik; P D Suzdak
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

Review 5.  FKBP immunophilins and Alzheimer's disease: a chaperoned affair.

Authors:  Weihuan Cao; Mary Konsolaki
Journal:  J Biosci       Date:  2011-08       Impact factor: 1.826

6.  Increases in [3H]FK-506 and [3H]L-N(G)-nitro-arginine binding in the rat brain after nigrostriatal dopaminergic denervation.

Authors:  T Araki; H Tanji; K Fujihara; H Kato; Y Itoyama
Journal:  Metab Brain Dis       Date:  1999-03       Impact factor: 3.584

Review 7.  FK506 and the role of immunophilins in nerve regeneration.

Authors:  B G Gold
Journal:  Mol Neurobiol       Date:  1997-12       Impact factor: 5.590

Review 8.  Role of immunophilins in recovery of erectile function after cavernous nerve injury.

Authors:  Sena F Sezen; Gwen Lagoda; Arthur L Burnett
Journal:  J Sex Med       Date:  2009-03       Impact factor: 3.802

Review 9.  Therapeutic potential of nerve growth factors in Parkinson's disease.

Authors:  T J Collier; C E Sortwell
Journal:  Drugs Aging       Date:  1999-04       Impact factor: 3.923

10.  Control of Alzheimer's amyloid beta toxicity by the high molecular weight immunophilin FKBP52 and copper homeostasis in Drosophila.

Authors:  Reiko Sanokawa-Akakura; Weihuan Cao; Kirsten Allan; Khyati Patel; Anupama Ganesh; Gary Heiman; Richard Burke; Francis W Kemp; John D Bogden; James Camakaris; Raymond B Birge; Mary Konsolaki
Journal:  PLoS One       Date:  2010-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.